Country
Netherlands
The European Medicines agency is recommending conditional approval of Tecartus (autologous anti-CD19-transduced CD3+ cells) for the treatment of relapsed or refractory mantle cell lymphoma.
Full text available to subscribers only. Click here for information on subscribing to MedNous.